机构：[1]Peking Univ, Peking Univ Peoples Hosp, Inst Hematol, Beijing, Peoples R China[2]Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China[3]China Japan Friendship Hosp, Beijing, Peoples R China[4]Peking Univ First Hosp, Beijing, Peoples R China[5]Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China[6]Beijing Tongren Hosp, Beijing, Peoples R China首都医科大学附属北京同仁医院首都医科大学附属同仁医院[7]Capital Med Univ, Xuanwu Hosp, Beijing, Peoples R China首都医科大学宣武医院[8]Capital Med Univ, Fuxing Hosp, Beijing, Peoples R China[9]Shanxi Prov Canc Hosp, Taiyuan, Peoples R China
第一作者机构：[1]Peking Univ, Peking Univ Peoples Hosp, Inst Hematol, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Yang Shenmiao,Feng Ru,Guo Xutao,et al.Outcomes and Clinical Practice Among Patient with Chronic Lymphocytic Leukemia Treated with Ibrutinib in China: A Real-World Experience[J].BLOOD.2024,144:7819-7820.doi:10.1182/blood-2024-210572.
APA：
Yang, Shenmiao,Feng, Ru,Guo, Xutao,Li, Zhenling,Ju, Qianqian...&Huang, Xiaojun.(2024).Outcomes and Clinical Practice Among Patient with Chronic Lymphocytic Leukemia Treated with Ibrutinib in China: A Real-World Experience.BLOOD,144,
MLA：
Yang, Shenmiao,et al."Outcomes and Clinical Practice Among Patient with Chronic Lymphocytic Leukemia Treated with Ibrutinib in China: A Real-World Experience".BLOOD 144.(2024):7819-7820
医学